Russell E. Ware

24.5k total citations · 3 hit papers
410 papers, 15.7k citations indexed

About

Russell E. Ware is a scholar working on Genetics, Hematology and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, Russell E. Ware has authored 410 papers receiving a total of 15.7k indexed citations (citations by other indexed papers that have themselves been cited), including 330 papers in Genetics, 285 papers in Hematology and 85 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Russell E. Ware's work include Hemoglobinopathies and Related Disorders (324 papers), Iron Metabolism and Disorders (208 papers) and Blood groups and transfusion (101 papers). Russell E. Ware is often cited by papers focused on Hemoglobinopathies and Related Disorders (324 papers), Iron Metabolism and Disorders (208 papers) and Blood groups and transfusion (101 papers). Russell E. Ware collaborates with scholars based in United States, Uganda and Canada. Russell E. Ware's co-authors include Sherri A. Zimmerman, William H. Schultz, Patrick T. McGann, Thad A. Howard, Winfred C. Wang, Banu Aygün, Ronald W. Helms, Miguel R. Abboud, Thomas R. Kinney and Nicole A. Mortier and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and The Lancet.

In The Last Decade

Russell E. Ware

394 papers receiving 15.3k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Management of Sickle Cell Disease

2014 1.0k citations Russell E. Ware, Jonathan C. Goldsmith et al. profile →
Causes and Outcomes of the Acute Chest Syndrome in Sickle Cell Disease

2000 800 citations Russell E. Ware et al. profile →
Sickle cell disease

2017 619 citations Russell E. Ware, Mariane de Montalembert et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Russell E. Ware	11.8k	10.4k	3.5k	1.7k	1.7k	410	15.7k
Elliott Vichinsky	20.2k 1.7×	16.8k 1.6×	5.8k 1.6×	3.3k 1.9×	2.0k 1.2×	432	24.2k
Thomas D. Coates	5.8k 0.5×	5.2k 0.5×	1.5k 0.4×	1.1k 0.6×	971 0.6×	296	9.8k
George R. Buchanan	5.0k 0.4×	8.0k 0.8×	2.3k 0.6×	589 0.3×	661 0.4×	313	12.6k
Ravi Bhatia	4.4k 0.4×	8.9k 0.9×	4.4k 1.3×	909 0.5×	4.8k 2.9×	463	21.8k
Mark R. Litzow	4.9k 0.4×	11.9k 1.1×	1.6k 0.4×	327 0.2×	5.5k 3.3×	597	18.9k
Jeff Szer	3.2k 0.3×	8.4k 0.8×	936 0.3×	692 0.4×	1.5k 0.9×	385	15.3k
Sy Ha	3.0k 0.3×	4.2k 0.4×	1.0k 0.3×	613 0.4×	1.4k 0.8×	341	14.3k
Stella M. Davies	2.1k 0.2×	8.7k 0.8×	3.4k 1.0×	525 0.3×	3.2k 1.9×	518	18.0k
Nicolaus Kröger	3.9k 0.3×	12.0k 1.2×	867 0.2×	291 0.2×	3.5k 2.1×	583	17.0k
Griffin P. Rodgers	3.4k 0.3×	2.6k 0.2×	900 0.3×	947 0.5×	1.5k 0.9×	174	6.7k

Countries citing papers authored by Russell E. Ware

Since Specialization

Citations

This map shows the geographic impact of Russell E. Ware's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Russell E. Ware with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Russell E. Ware more than expected).

Fields of papers citing papers by Russell E. Ware

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Russell E. Ware. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Russell E. Ware. The network helps show where Russell E. Ware may publish in the future.

Co-authorship network of co-authors of Russell E. Ware

This figure shows the co-authorship network connecting the top 25 collaborators of Russell E. Ware. A scholar is included among the top collaborators of Russell E. Ware based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Russell E. Ware. Russell E. Ware is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ambrose, Emmanuela E., et al.. (2025). Hydroxyurea to decrease stroke risk in children with sickle cell anemia: a systematic review and meta-analysis. PubMed. 1(1). 100001–100001.

Power‐Hays, Alexandra, Kathryn McElhinney, Thomas N. Williams, et al.. (2025). Hydroxyurea pharmacokinetics in children with sickle cell anemia across different global populations. Blood Advances. 10(2). 418–427.

Mochamah, George, Johnstone Makale, Steven Ger Nyanjom, et al.. (2025). Erythrocyte alloimmunization in children with sickle cell anemia living in Kilifi, Kenya. SHILAP Revista de lepidopterología. 1(2). 100016–100016.

Power‐Hays, Alexandra, George Tomlinson, Léon Tshilolo, et al.. (2024). Reducing transfusion utilization for children with sickle cell anemia in sub‐Saharan Africa with hydroxyurea: Analysis from the phase I/II REACH trial. American Journal of Hematology. 99(4). 625–632. 6 indexed citations

Costa, Enrico, Antonella Isgrò, Mariane de Montalembert, et al.. (2024). Successes and pitfalls in orphan drug development for sickle cell disease. Blood Advances. 8(10). 2455–2465. 7 indexed citations

Smart, Luke R., Catherine Segbefia, Teresa Latham, et al.. (2023). Prospective identification of variables as outcomes for treatment (PIVOT): study protocol for a randomised, placebo-controlled trial of hydroxyurea for Ghanaian children and adults with haemoglobin SC disease. Trials. 24(1). 603–603. 2 indexed citations

Opoka, Robert O., Phillip Kasirye, Heather Hume, et al.. (2023). Cost-Effectiveness of Hydroxyurea for Sickle Cell Anemia in a Low-Income African Setting: A Model-Based Evaluation of Two Dosing Regimens. PharmacoEconomics. 41(12). 1603–1615. 7 indexed citations

Safeukui, Innocent, Russell E. Ware, Narla Mohandas, & Kasturi Haldar. (2023). Simultaneous adjunctive treatment of malaria and its coevolved genetic disorder sickle cell anemia. Blood Advances. 7(19). 5970–5981. 3 indexed citations

Rankine‐Mullings, Angela, Russell Keenan, Subarna Chakravorty, et al.. (2023). Efficacy, safety, and pharmacokinetics of a new, ready-to-use, liquid hydroxyurea in children with sickle cell anemia. Blood Advances. 7(16). 4319–4322. 5 indexed citations

10.

Sadaf, Alina, Min Dong, Teresa Latham, et al.. (2021). Pharmacokinetics of L-Glutamine (Endari) in Pediatric and Adult Sickle Cell Disease Patients: A Phase 4, Open-Label, Single-Center Study. Blood. 138(Supplement 1). 980–980. 1 indexed citations

11.

Opoka, Robert O., Christopher M. Ndugwa, Teresa Latham, et al.. (2017). Novel use Of Hydroxyurea in an African Region with Malaria (NOHARM): a trial for children with sickle cell anemia. Blood. 130(24). 2585–2593. 98 indexed citations

12.

Schaefer, Beverly A., Charles Kiyaga, Thad A. Howard, et al.. (2016). Hemoglobin variants identified in the Uganda Sickle Surveillance Study. Blood Advances. 1(1). 93–100. 8 indexed citations

13.

Kasirye, Phillip, Heather Hume, Robert O. Opoka, et al.. (2016). Novel Use of Hydroxyurea in an African Region With Malaria: Protocol for a Randomized Controlled Clinical Trial. JMIR Research Protocols. 5(2). e110–e110. 18 indexed citations

14.

Rankine‐Mullings, Angela, Marvin Reid, Jennifer Knight‐Madden, et al.. (2016). EXpanding Treatment for Existing Neurological Disease (EXTEND): An Open-Label Phase II Clinical Trial of Hydroxyurea Treatment in Sickle Cell Anemia. JMIR Research Protocols. 5(3). e185–e185. 9 indexed citations

15.

Ware, Russell E.. (2015). Optimizing hydroxyurea therapy for sickle cell anemia. Hematology. 2015(1). 436–443. 40 indexed citations

16.

Lederman, Howard M., Margaret A. Connolly, Ram Kalpatthi, et al.. (2014). Immunologic Effects of Hydroxyurea in Sickle Cell Anemia. PEDIATRICS. 134(4). 686–695. 38 indexed citations

17.

Thornburg, Courtney D., Beatrice Files, Zhaoyu Luo, et al.. (2012). Impact of hydroxyurea on clinical events in the BABY HUG trial. Blood. 120(22). 4304–4310. 184 indexed citations

18.

Zimmerman, Sherri A., et al.. (2007). Hydroxyurea therapy lowers transcranial Doppler flow velocities in children with sickle cell anemia. Blood. 110(3). 1043–1047. 149 indexed citations

19.

Zimmerman, Sherri A., Frank Malinoski, & Russell E. Ware. (1998). Immunologic effects of anti-D (WinRho-SD) in children with immune thrombocytopenic purpura. American Journal of Hematology. 57(2). 131–138. 17 indexed citations

20.

Zimmerman, Sherri A., Frank Malinoski, & Russell E. Ware. (1998). Immunologic effects of anti‐D (WinRho‐SD) in children with immune thrombocytopenic purpura. American Journal of Hematology. 57(2). 131–138. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact